期刊文献+

多重PCR检测临床产ESBLs大肠埃希菌的耐药基因型研究 被引量:7

Multiplex PCR assay for genotype of ESBLs-producing Escherichia coli in clinical isolates
下载PDF
导出
摘要 目的了解产超广谱β-内酰胺酶(ESBLs)大肠埃希菌的耐药性、产ESBLs的阳性率及耐药基因之间的关系。方法采用Kirby-Bauer(K-B)琼脂扩散法检测120株临床分离的大肠埃希菌对18种抗生素的耐药性,用酶抑制剂增强实验纸片法检测产ESBLs菌株,运用多重PCR技术检测相关耐药基因,用DNA序列分析确认基因亚型。结果120株大肠埃希菌产ESBLs的有51株,阳性率为42.5%。120株大肠埃希菌对亚胺培南全部敏感,产ESBLs的大肠埃希菌对头孢唑啉、头孢噻肟、头孢曲松、头孢哌酮、头孢他啶等头孢类抗菌药物的耐药率高达100%;51株产ESBLs菌株其中46株扩增到CTX-M型耐药基因,44株扩增到TEM型基因,2株扩增到SHV基因,1株OXA型基因,未检出PER和VEB型。结论大肠埃希菌产ESBLs较高,耐药显著,碳青酶烯类抗生素是目前治疗产ESBLs大肠埃希菌最有效的药物;产ESBLs大肠埃希菌的主要基因型别为CTX-M型和TEM型。 Objective To investigate the production of extended - spectrum β-lactamases (ESBLs) of the drug resistance of Esch- erichia coli producing ESBLs positive rate and the relationship with the resistance gene. Methods The K - B agar diffusion assay the resistance of 120 clinical isolates of Escherichia coli to the 18 kinds of antibiotics, using enzyme inhibitors enhance paper to test phenotype of ESBLs, using multiplex PCR to detect related resistance gene, and using DNA sequence analysis to confirmed the gene subtypes. Results 51 of 120 Escherichia coli producing ESBLs, the positive rate was 42.5%. All of 120 isolates are sensitive to imipenem, the antimicrobial resistance rate of ESBLs - producing isolats to cefazolin, cefotaxime, ceftriaxone, cefoperazone, ceftazidime and other cephalosporins was as high as 100% ; 51 strains producing ESBLs which amplified 46 to CTX - M - type resistance gene, amplified by 44 to TEM - type genes, two amplified SHV genes and one OXA-type genes. PER - type and VEB - type were negative. Conclusion Carbapenem antibiotics is currently the most effective drugs to treatment Escherichia coli which producing ESBLs ; the major genotypes were CTX - M - type and TEM - type.
出处 《安徽医学》 2009年第10期1156-1159,共4页 Anhui Medical Journal
关键词 超广谱Β-内酰胺酶 大肠埃希菌 多重PCR 耐药性 基因型 ESBLs Escherichia coli Multiplex PCR Resistance Genotype
  • 相关文献

参考文献18

  • 1季淑娟,顾怡明,谭文涛,王丹丹,冯羡菊,周志慧,俞云松,陈亚岗,李兰娟.中国部分地区大肠埃希菌和肺炎克雷伯菌超广谱β内酰胺酶基因型研究[J].中华检验医学杂志,2004,27(9):590-593. 被引量:172
  • 2汪复.2005中国CHINET细菌耐药性监测结果[J].中国感染与化疗杂志,2006,6(5):289-295. 被引量:284
  • 3Fang H, Lundberg C, Olsson -Liljequist B, et al. Molecular epidemiologieal analysis of Escheriehia eoli isolates producing extended - spectrum beta - lactamases for identifica- tion of nosoeomial outbreaks in Stockholm, Sweden. Clin Microbiol,2004,42 ( 12 ) :5917 - 5920.
  • 4Monstein HJ, Osthohn- Balkhed A, Nilsson MV, et al. Multiplex PCR amplification assay for the detection of blaSHV,blaTEM, and blaCTX- M genes inEnterobacteriaceae. APMIS ,2007,115 (12) : 1400 - 1408.
  • 5Ko CS, Sung JY, Koo SH, et al. Prevalence of Extended - Spectrum- lactamases in Escherichia coli and Klebsiella pneumoniae from Daejeon. Korean J Lab Med ,2007,27 ( 5 ) : 344 - 350.
  • 6Ouellette M, Bissonnette L, Roy PH. Precise insertion of antibiotic resistance determinants into Tn21 - like transposons : nucleotide sequence of the OXA - 1 beta - lactamase gene. Proc Natl Acad Sci USA, 1987,84 (21 ) :7378 - 7382.
  • 7Kang JH, Bae IK, Kwon SB, et al. Prevalence of Ambler Class A Extended - Spectrum beta - Lacta - mase - Produ- cing Eseheriehia coli and Klebsiella pneumoniae Isolates in Korea. Korean J Clin Mierobio1,2005,8 ( 1 ) : 17 - 25.
  • 8Gniadkowski M. Evolution and epidemiology of extended - spectrum beta - lactamases (ESBLs) and ESBL - producing microorganisms. Clin Microbiol Infect, 2001,7 ( 11 ) :597 - 608.
  • 9Nathisuwan S, Burgess DS, Lewis JS, et al. Extended - spectrum beta - lactamases: epidemiology, detection and treatment. Pharmacotherapy ,2001,21 ( 8 ) :902 - 925.
  • 10Bradford PA. Extended- spectrum β- lactamases in the 21st Century- characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev,2001, 14(4) :933 -951.

二级参考文献46

共引文献461

同被引文献66

  • 1韦洁宏,黄烈,林广城,刘键,杨来智,陆学东.产ESBLs肺炎克雷伯菌基因型分析[J].现代检验医学杂志,2007,22(3):37-39. 被引量:4
  • 2Clinical and Laboratory Standards Institute. PerformanceStandards for Antimicrobial Susceptibility Testing[S]. Twen-ty-Second Informational Supplement M100-S21 . Vol 31.Nol,2011.
  • 3van der Bij AK,Peirano G,Goessens WH,et al. Clinical andmolecular characteristics of extended-spectrum- lactamase-producing Escherichia coli causing bacteremia in the Rotter-dam Area,Netherlands[J]. Antimicrob Agents Chemother,2011, 55(7):3576-3578.
  • 4Zhanel GG,DeCorby M,Adam H,et al. Prevalence of anti-microbial-resistant pathogens in Canadian hospitals : results ofthe Canadian Ward Surveillance Study (CANWARD 2008)[J], Antimicrob Agents Chemother, 2010, 54 ( 11 ) : 4684-4693.
  • 5Galas M,Decousser JW, Breton N,et al. Nationwide studyof the prevalence, characteristic, and molecular, epidemiolo-gy of extended-spectrum-β-lactamase-producing Enterobacte-riaceae in France[J]. Antimicrob Agents Chemother, 2008,52(2):786-789.
  • 6Empel J, Baraniak A, Literacka E,et al. Molecular survey ofβ-lactamases conferring resistance to newer β-lactams in En-terobacteriaceae isolates from Polish[J], Antimicrob AgentsChemother, 2008, 52(7):2449-2454.
  • 7Diaz MA, Hernaandez-Bello JR, Rodriguez-Banno J, et al. Di-versity of Escherichia coli strains producing extended-spec-trum β-lactamases in Spain: second nationwide study [J]. JClin Microbiol, 2010, 48(8):2840-5845.
  • 8Wang P, Hu F, Xiong Z, et al. Susceptibility of extend- ed -spectrum -beta- lactamase-producing Enterobacteriace- ae according to the new CLSI breakpoint [ J ]. J Clin Mi- crobiol, 2011, 49(9) :3127-3131.
  • 9Clinical and Laboratory Standards Institute (CLSI). Per- formance Standards for Anfimicrobial Susceptibility Tes- ting [ S ]. Twenty-Second Informational Supplement. 中华检验医学杂志[J].2012,32(3).
  • 10Rodriguez-Villalobos H, Bogaerts P, Berhin C, et al. Trends in production of extended- spectrum- beta -lacta- mases among Enterobacteriaceae of clinical interest: re- sults of a nationwide survey in Belgian hospitals [ J ]. J Antimicrob Chemother, 2011, 66( 1 ) :3747.

引证文献7

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部